<i>APOE</i> genotype regulates pathology and disease progression in synucleinopathy

Albert A. Davis(Washington University in St. Louis), Casey E. Inman(Washington University in St. Louis), Zachary M. Wargel(Washington University in St. Louis), Umber Dube(Washington University in St. Louis), Brittany M. Freeberg(Washington University in St. Louis), Alexander Galluppi(Washington University in St. Louis), Jessica N. Haines(Washington University in St. Louis), Dhruva D. Dhavale(Washington University in St. Louis), Rebecca L. Miller(Washington University in St. Louis), Fahim A. Choudhury(Washington University in St. Louis), Patrick M. Sullivan(Duke Medical Center), Carlos Cruchaga(Washington University in St. Louis), Joel S. Perlmutter(Washington University in St. Louis), Jason D. Ulrich(Washington University in St. Louis), Bruno A. Benítez(Washington University in St. Louis), Paul T. Kotzbauer(Washington University in St. Louis), David M. Holtzman(Washington University in St. Louis)
Science Translational Medicine
February 5, 2020
10.1126/scitranslmed.aay3069
Cited by 179Open Access
Full Text

Abstract

APOE genotype regulates disease development in mouse models of α-synucleinopathy and affects cognition in patients with Parkinson’s disease.

Related Papers

No related papers found

Powered by citation graph analysis